Article
Medicine, General & Internal
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Kluempen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater
Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Sudha Kodali, Akshay Shetty, Soumya Shekhar, David W. Victor, Rafik M. Ghobrial
Summary: Cholangiocarcinoma, a tumor arising from differentiation of cholangiocytes, can develop anywhere in the biliary tree. Early diagnosis allows for surgical resection, while late-stage intrahepatic cholangiocarcinoma cases may require chemotherapy, locoregional therapies, and radiation as treatment options.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Yuki Bekki, Dagny Von Ahrens, Hideo Takahashi, Myron Schwartz, Ganesh Gunasekaran
Summary: Understanding the risk factors, patterns, and treatment options for intrahepatic cholangiocarcinoma recurrence is crucial for tailoring postoperative surveillance and selecting treatment strategies. Re-resection may be considered for selected patients at experienced centers, potentially leading to long-term survival. ICC remains a challenging disease, but advances in understanding its genomic landscape are paving the way for personalized treatment options.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Mackenzie Owen, Mina S. Makary, Eliza W. Beal
Summary: This review examines locoregional therapy approaches for intrahepatic cholangiocarcinoma and summarizes the current literature. Locoregional therapies include thermal ablation, transarterial chemoembolization, transarterial radioembolization, external beam radiotherapy, stereotactic body radiotherapy, hepatic arterial infusion of chemotherapy, irreversible electroporation, and brachytherapy. These therapies are effective in prolonging overall survival and further research is needed to determine their comparative efficacy and optimal treatment strategies.
Review
Oncology
Amram Kupietzky, Arie Ariche
Summary: This paper reviews the surgical management of intrahepatic cholangiocarcinoma (ICC), highlighting surgical resection as the only curative treatment for ICC.
Article
Gastroenterology & Hepatology
Fernando Carapeto, Behnaz Bozorgui, Rachna T. Shroff, Sharmeen Chagani, Luisa Solis Soto, Wai Chin Foo, Ignacio Wistuba, Funda Meric-Bernstam, Ahmed Shalaby, Milind Javle, Anil Korkut, Lawrence N. Kwong
Summary: This study integrated immunohistochemistry with next-generation sequencing to analyze intrahepatic CCA samples and found that T-cell and immune checkpoint markers were enriched at tumor margins compared to the center. High PD-1 or LAG-3 and low CD3/CD4/ICOS in the tumor center were associated with poor survival. Loss-of-function mutations in BRCA1-associated protein-1 were associated with elevated expression of the immunosuppressive checkpoint marker B7-H4.
Article
Gastroenterology & Hepatology
Thomas Boerner, Esther Drill, Linda M. Pak, Bastien Nguyen, Carlie S. Sigel, Alexandre Doussot, Paul Shin, Debra A. Goldman, Mithat Gonen, Peter J. Allen, Vinod P. Balachandran, Andrea Cercek, James Harding, David B. Solit, Nikolaus Schultz, Ritika Kundra, Henry Walch, Michael D'Angelica, Ronald P. DeMatteo, Jeffrey Drebin, Nancy E. Kemeny, T. Peter Kingham, Amber L. Simpson, Jaclyn F. Hechtman, Efsevia Vakiani, Maeve A. Lowery, J. N. M. Ijzermans, S. Buettner, B. Groot Koerkamp, M. Doukas, Rohit Chandwani, William R. Jarnagin
Summary: Genetic alterations in iCCA, including TP53, KRAS, and CDKN2A mutations, are associated with poorer prognosis, especially in advanced disease, independent of clinical and pathological variables. Combining targeted tumor sequencing with clinical variables may help identify patient subgroups with poor outcomes, regardless of treatment strategy.
Article
Medicine, General & Internal
Tim Reese, Gregor Pagel, Bettina A. Bause, York von Rittberg, Kim C. Wagner, Karl J. Oldhafer
Summary: For intrahepatic cholangiocarcinoma (iCCA), complex liver resections are justified in selected patients and survival rates are comparable to conventional liver resections. Survival in iCCA is affected by resection margins and UICC stage, rather than the complexity of the case.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Jie Hu, Yi-Ning Wang, Dan-Jun Song, Jin-Peng Tan, Ya Cao, Jia Fan, Zheng Wang, Jian Zhou
Summary: This study demonstrated the diagnostic value of plasma miR-21, miR-122, and CA19-9 in iCCA, and established a novel three-marker model with high accuracy for differentiating iCCA from controls. This model showed great clinical value, especially for diagnosing early iCCA and CA19-9 negative iCCA.
Article
Biochemistry & Molecular Biology
Serena Mancarella, Grazia Serino, Sergio Coletta, Raffaele Armentano, Francesco Dituri, Francesco Ardito, Andrea Ruzzenente, Isabel Fabregat, Gianluigi Giannelli
Summary: The study demonstrates that Crenigacestat effectively inhibits NOTCH1 and HES1, while not affecting tumor progression. The drug also triggers a strong immune response and blocks neovascularization in the tumor ecosystem without affecting fibrotic reactions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Katsuya Toshida, Shinji Itoh, Noboru Harada, Akinari Morinaga, Kyohei Yugawa, Takahiro Tomiyama, Yukiko Kosai-Fujimoto, Takahiro Tomino, Takeshi Kurihara, Yoshihiro Nagao, Kazutoyo Morita, Yoshinao Oda, Tomoharu Yoshizumi
Summary: The association between tumor microenvironment (TME) and cancer-associated fibroblasts (CAFs) in intrahepatic cholangiocarcinoma (ICC) progression is poorly understood. This study aimed to investigate the role of specific microRNAs (miRNAs) in extracellular vesicles (EVs) derived from CAFs in ICC progression. The results showed that miR-493-5p in CAF-derived EVs promoted tumor cell proliferation by suppressing CARTPT expression in ICC cells.
Review
Oncology
Felix Krenzien, Nora Nevermann, Alina Krombholz, Christian Benzing, Philipp Haber, Uli Fehrenbach, Georg Lurje, Uwe Pelzer, Johann Pratschke, Moritz Schmelzle, Wenzel Schoening
Summary: This review discusses multimodality treatment strategies for intrahepatic cholangiocarcinoma (iCC). Surgical resection remains the only potentially curative therapeutic option, and adjuvant systemic treatment is recommended. Targeted therapies and interventional treatments such as high-dose brachytherapy and transarterial chemoembolization are being evaluated for unresectable iCC. Any treatment strategy should be discussed in a multidisciplinary tumor board and guided by specialized treatment centers.
Review
Medicine, General & Internal
Ruslan Alikhanov, Anna Dudareva, Miguel Angel Trigo, Alejandro Serrablo
Summary: Intrahepatic cholangiocarcinoma (iCCA) usually requires surgical treatment, even in cases of macrovascular invasion, as surgery offers the only chance of cure. However, tumor recurrence is common post-surgery and long-term prognosis is poor, indicating the need for multimodal treatment to improve outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Fei Liu, Qing Xu, Parbatraj Regmi, Fu-Yu Li, Yi-Xin Lin
Summary: This article reported a rare case of LEL-ICC in a Chinese female, which was discovered during a pancreatitis examination. MRI examination revealed a 1.1x1.3 cm tumor in the left lobe of the liver. The definitive diagnosis was confirmed through histopathological examination, and the patient achieved successful treatment through surgical resection.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Liangqing Dong, Dayun Lu, Ran Chen, Youpei Lin, Hongwen Zhu, Zhou Zhang, Shangli Cai, Peng Cui, Guohe Song, Dongning Rao, Xinpei Yi, Yingcheng Wu, Nixue Song, Fen Liu, Yunhao Zou, Shu Zhang, Xiaoming Zhang, Xiaoying Wang, Shuangjian Qiu, Jian Zhou, Shisheng Wang, Xu Zhang, Yongyong Shi, Daniel Figeys, Li Ding, Pei Wang, Bing Zhang, Henry Rodriguez, Qiang Gao, Daming Gao, Hu Zhou, Jia Fan
Summary: This study performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) and revealed important features of iCCA pathogenesis. It identified subgroup-specific biomarkers and provided valuable insights into molecular pathogenesis and therapeutic opportunities in iCCA.
Article
Hematology
Eleonora Ghisoni, Laura Marandino, Pasquale Lombardi, Alessandro Bonzano, Paolo Becco, Massimo Aglietta, Marco Fizzotti, Francesca Gay, Delia Rota Scalabrini
ACTA HAEMATOLOGICA
(2020)
Article
Biochemistry & Molecular Biology
Paola Ostano, Maurizia Mello-Grand, Debora Sesia, Ilaria Gregnanin, Caterina Peraldo-Neia, Francesca Guana, Elena Jachetti, Antonella Farsetti, Giovanna Chiorino
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Oncology
Sarah N. Mapelli, Domenico Albino, Maurizia Mello-Grand, Dheeraj Shinde, Manuel Scimeca, Rita Bonfiglio, Elena Bonanno, Giovanna Chiorino, Ramon Garcia-Escudero, Carlo V. Catapano, Giuseppina M. Carbone
Article
Oncology
Ankit Patel, Lucia Fraile Garcia, Viviana Mannella, Luke Gammon, Tiffanie-Marie Borg, Tania Maffucci, Maria Scatolini, Giovanna Chiorino, Elisabetta Vergani, Monica Rodolfo, Andrea Maurichi, Christian Posch, Rubeta N. Matin, Catherine A. Harwood, Daniele Bergamaschi
Review
Oncology
Annamaria Massa, Chiara Varamo, Francesca Vita, Simona Tavolari, Caterina Peraldo-Neia, Giovanni Brandi, Alessandro Rizzo, Giuliana Cavalloni, Massimo Aglietta
Article
Oncology
Caterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, Francesca Guana, Ilaria Gregnanin, Donatella Boschi, Simonetta Oliaro-Bosso, Agnese Chiara Pippione, Andrea Carenzo, Loris De Cecco, Stefano Cavalieri, Arianna Micali, Federica Perrone, Gianluca Averono, Paolo Bagnasacco, Riccardo Dosdegani, Laura Masini, Marco Krengli, Paolo Aluffi-Valletti, Guido Valente, Giovanna Chiorino
Summary: The study found that genes in HPV-negative OPSCCs are related to the immune system, while those in HPV-positive OPSCCs are mainly involved in glutathione derivative biosynthesis and xenobiotic metabolism. A potential prognostic biomarker, AKR1C3, was identified, and inhibition of it can enhance the effectiveness of Cisplatin.
Article
Clinical Neurology
Federica Morani, Stefano Doccini, Giovanna Chiorino, Fabiana Fattori, Daniele Galatolo, Elisa Sciarrillo, Federica Gemignani, Stephan Zuchner, Enrico Silvio Bertini, Filippo Maria Santorelli
Summary: This study used proteomics data to identify dysregulated biological processes related to neuroinflammation, synaptogenesis, and cell engulfment in both ARSACS patients and SACS KO neuroblastoma cells. The findings suggest potential biomarkers for ARSACS and indicate dysfunctional pathways in the disease that could be targeted for future therapeutic interventions.
FRONTIERS IN NEUROLOGY
(2021)
Article
Oncology
Simona Nanni, Aurora Aiello, Chiara Salis, Agnese Re, Chiara Cencioni, Lorenza Bacci, Francesco Pierconti, Francesco Pinto, Cristian Ripoli, Paola Ostano, Silvia Baroni, Giacomo Lazzarino, Barbara Tavazzi, Dario Pugliese, PierFrancesco Bassi, Claudio Grassi, Simona Panunzi, Giovanna Chiorino, Alfredo Pontecorvi, Carlo Gaetano, Antonella Farsetti
Summary: The study revealed the significant role of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in prostate cancer metabolism, with its silencing causing metabolic reprogramming and reverting the phenotype of prostate cancer cells to that of normal prostate cells.
Article
Immunology
Roberta Sulsenti, Barbara Frossi, Lucia Bongiovanni, Valeria Cancila, Paola Ostano, Irene Fischetti, Claudia Enriquez, Francesca Guana, Giovanna Chiorino, Claudio Tripodo, Carlo E. Pucillo, Mario P. Colombo, Elena Jachetti
Summary: Levetiracetam has the potential to be an effective drug for the treatment of prostate cancer by targeting both MCs and NEPC cells. Experimental results demonstrate that levetiracetam can directly inhibit NEPC development and block adenocarcinoma progression through the inhibition of some MCs functions.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Caterina Peraldo-Neia, Annamaria Massa, Francesca Vita, Marco Basirico, Chiara Raggi, Paola Bernabei, Paola Ostano, Laura Casorzo, Mara Panero, Francesco Leone, Giuliana Cavalloni, Massimo Aglietta
Summary: Intrahepatic cholangiocarcinoma (ICC) has limited prognosis and therapies, with gemcitabine-based therapy showing poor benefits due to resistance. The study aimed to establish and characterize an Italian ICC cell line, 82.3, displaying resistance to multiple drugs. This model could help investigate drug resistance mechanisms and identify alternative therapies for better prognosis.
Article
Cell Biology
Eirini Chrysanthou, Emir Sehovic, Paola Ostano, Giovanna Chiorino
Summary: Female melanoma patients have a lower incidence and better prognosis compared to males. Through statistical analysis of melanoma gene expression datasets, this study reveals sex and stage differences in gene expression. Specifically, females have lower gene expression variability in normal skin, nevi, and early-stage melanomas, while males have lower variability in stage III melanomas. Gene expression differences between sexes are most notable in non-melanoma and early-stage melanoma samples.
Article
Oncology
Silvia Marconi, Michela Croce, Giovanna Chiorino, Giovanni Rossi, Francesca Guana, Aldo Profumo, Paola Ostano, Angela Alama, Luca Longo, Giuseppa De Luca, Mariella Dono, Maria Giovanna Dal Bello, Marco Ponassi, Camillo Rosano, Paolo Romano, Zita Cavalieri, Massimiliano Grassi, Marco Tagliamento, Lodovica Zullo, Consuelo Venturi, Chiara Dellepiane, Luca Mastracci, Elisa Bennicelli, Paolo Pronzato, Carlo Genova, Simona Coco
Summary: This study performed in-depth analysis of circulating markers in early-stage non-small cell lung cancer (NSCLC) to identify a prognostic score for cancer recurrence prediction. The study found that the overexpression of Exo-miR-130a-3p and the reduction of FpA (2-16) were associated with cancer relapse, and high-risk patients had shorter disease-free survival. The overexpression of miR-130a-3p may lead to dysregulation of angiogenesis and coagulation pathways.